Methylandrostenediol

Methandriol (INN) (brand names Crestabolic, Cytobolin, Diandren, Madiol, Stenediol, Mestenediol), also known as methylandrostenediol, as well as 17α-methylandrost-5-ene-3β,17β-diol, is a synthetic, orally active androgen and anabolic steroid (AAS) which was developed by Organon and is used in both oral and injectable (as methandriol dipropionate, methandriol propionate, or methandriol bisenanthoyl acetate) formulations. It is a 17α-alkylated AAS and the 17α-methylated derivative of the endogenous androgen prohormone androstenediol. Methandriol (INN) (brand names Crestabolic, Cytobolin, Diandren, Madiol, Stenediol, Mestenediol), also known as methylandrostenediol, as well as 17α-methylandrost-5-ene-3β,17β-diol, is a synthetic, orally active androgen and anabolic steroid (AAS) which was developed by Organon and is used in both oral and injectable (as methandriol dipropionate, methandriol propionate, or methandriol bisenanthoyl acetate) formulations. It is a 17α-alkylated AAS and the 17α-methylated derivative of the endogenous androgen prohormone androstenediol. Methandriol has been used in the treatment of breast cancer in women. It has been reported to be almost as virilizing as comparable doses of testosterone propionate and methyltestosterone in women. Methandriol remains marketed for clinical use only in Taiwan and for veterinary use (as methandriol dipropionate) only in Australia. Methandriol (brand name Androteston M, Notandron, Protandren) was previously marketed as 25 mL and 50 mg/mL aqueous suspensions for use by intramuscular injection. Methandriol was first synthesized in 1935 along with methyltestosterone and mestanolone.